GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omni Bio Pharmaceutical Inc (GREY:OMBP) » Definitions » Capex-to-Operating-Income

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Capex-to-Operating-Income : 0.00 (As of Dec. 2014)


View and export this data going back to 2007. Start your Free Trial

What is Omni Bio Pharmaceutical Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Omni Bio Pharmaceutical's Capital Expenditure for the three months ended in Dec. 2014 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2014 was $-0.52 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Omni Bio Pharmaceutical Capex-to-Operating-Income Historical Data

The historical data trend for Omni Bio Pharmaceutical's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omni Bio Pharmaceutical Capex-to-Operating-Income Chart

Omni Bio Pharmaceutical Annual Data
Trend Dec06 Dec07 Dec08 Mar09 Mar10 Mar11 Mar12 Mar13 Mar14
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only - - - - -

Omni Bio Pharmaceutical Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Omni Bio Pharmaceutical's Capex-to-Operating-Income

For the Biotechnology subindustry, Omni Bio Pharmaceutical's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omni Bio Pharmaceutical's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omni Bio Pharmaceutical's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Omni Bio Pharmaceutical's Capex-to-Operating-Income falls into.



Omni Bio Pharmaceutical Capex-to-Operating-Income Calculation

Omni Bio Pharmaceutical's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2014 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.912
=N/A

Omni Bio Pharmaceutical's Capex-to-Operating-Income for the quarter that ended in Dec. 2014 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.522
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Omni Bio Pharmaceutical  (GREY:OMBP) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Omni Bio Pharmaceutical Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Omni Bio Pharmaceutical's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
5350 South Roslyn, Suite 430, Greenwood Village, CO, USA, 80111
Omni Bio Pharmaceutical Inc is a US-based biopharmaceutical company, which is engaged in the exploration of new methods of use of alpha-1 antitrypsin (AAT). It offers AAT, a naturally occurring protein that is essential for normal liver and lung function and has been purified from human blood to treat patients suffering from emphysema due to AAT-deficiency. Further, it focuses on the research and development efforts of advancing its first recombinant molecule, AAT and an Fc component of immunoglobulin (AAT-Fc 2) into clinical trials. Geographically these activities are functioned through the region of US.

Omni Bio Pharmaceutical (Omni Bio Pharmaceutical) Headlines

No Headlines